+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 128 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating BLU-5937, an oral drug, in adults with refractory chronic cough, including unexplained chronic cough, in a randomized, double-blind, placebo-controlled Phase 3 study. The main goal is to assess how BLU-5937 affects 24-hour cough frequency over 24 weeks. This study also monitors safety by tracking adverse events and changes in various health parameters during the treatment period. Participants are randomly assigned to one of three groups BLU-5937 25 mg twice daily, BLU-5937 50 mg twice daily, or a matching placebo taken twice daily. The treatment lasts for 24 weeks, and participants receive their assigned oral medication regularly throughout this time. The study uses a parallel-arm design and includes an extension in China. During the study, participants undergo assessments including cough frequency measurement, vital signs, blood tests for hormones and chemistry, hematology, and ECGs at baseline and Week 24. Researchers also evaluate cough severity and quality of life using questionnaires. Safety is closely monitored by recording adverse events, treatment discontinuations, and laboratory changes. The total participation duration is 24 weeks, with follow-up assessments at specified intervals.

Age: 18Years - 80YearsAll GendersPhase 3
38 locations
A

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a drug called B007 compared to cyclosporine in treating adults with primary membranous nephropathy, a kidney condition. This study is a multicenter, randomized, controlled, open-label trial conducted in phases II and III to better understand treatment options for this disease. Participants will be randomly assigned to receive either B007 or cyclosporin capsules. B007 is given by subcutaneous injection on days 1 and 15, while cyclosporin capsules are taken orally at a dose of 3.5 mg per kg of body weight per day. The study will observe participants over about two years to assess remission rates and monitor safety. During the trial, participants will undergo laboratory tests and assessments to track overall, complete, and partial remission rates. Researchers will also monitor any treatment-emergent adverse events or serious side effects. Participants must meet specific kidney function criteria and will be followed closely throughout the study period until its completion in late 2026.

Age: 18Years - 80YearsAll GendersPhase 2Phase 3
21 locations
P

Actively Recruiting

Researchers are evaluating TQB2102 for injection, a new antibody-coupled drug that targets two different parts of the HER2 protein on tumor cells. This study focuses on patients with unresectable locally advanced, recurrent, or metastatic HER2-positive gastroesophageal adenocarcinoma. The trial aims to assess the effectiveness and safety of TQB2102 combined with benmelstobart or penpulimab, with or without chemotherapy, in this patient group. This is a Phase II randomized study sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Participants receive TQB2102 for injection and either benmelstobart or penpulimab, both given intravenously every three weeks. Chemotherapy is taken orally from Day 1 to Day 15 in each 21-day treatment cycle. There are three study groups, each involving different combinations and doses of TQB2102, benmelstobart, penpulimab, and chemotherapy. Treatment continues through multiple cycles as determined by the study protocol. During the study, participants undergo regular assessments including scans and tests to measure tumor response and disease progression. Researchers monitor outcomes like the objective response rate, progression-free survival, duration of response, overall survival, and any adverse events. The study includes follow-up periods to track safety and effectiveness, with an average observation of up to three years. Participants are closely monitored throughout the treatment and follow-up phases for their health and response to therapy.

Age: 18Years - 75YearsAll GendersPhase 2
39 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of TQB6411 for injection in adults with advanced lung cancer. This phase IbII clinical trial aims to find the recommended phase II dosage and assess how well the treatment works in shrinking tumors or controlling the disease. The study is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and focuses on patients aged 18 to 75 years with confirmed lung cancer. Participants will receive TQB6411 injections either every 21 days or every 28 days as treatment cycles. The study involves only one treatment group where all participants receive TQB6411. Each cycle of treatment is followed by assessments to monitor response and safety. The trial includes dose evaluation and efficacy measurement over several months, with extended follow-up for survival and side effects lasting up to three years. During the study, participants will undergo medical evaluations including laboratory tests, imaging scans to measure tumors, and monitoring of adverse events. Blood samples will be taken to study drug levels and antibodies. The main outcomes measured include tumor response rates, disease control, duration of response, progression-free and overall survival. Safety is closely monitored throughout the study. The total participation time may last up to three years, including treatment and follow-up visits.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
38 locations
T

Actively Recruiting

Researchers are investigating a combination therapy of BNT326 and pumitamig for adults with advanced or metastatic non-small cell lung cancer NSCLC that has either relapsed, progressed, or is treatment-nafve. The study includes multiple parts to find the best dose levels, assess safety and tolerability, and evaluate how well the therapy works to shrink tumors in this patient population. The trial is open-label and conducted across multiple sites, focusing on participants with confirmed advanced NSCLC where no curative treatment is available. The study consists of three parts Part 1 focuses on finding safe dose combinations of BNT326 with pumitamig Part 2a expands the dose evaluation to examine preliminary effectiveness and safety and Part 2b randomizes participants to optimize dosing and assess the contribution of each therapy component. Participants with prior treatment and those who are treatment-nafve are enrolled in different cohorts. Treatment is administered via intravenous infusion, and dose levels for Part 2b are determined based on earlier results. Participants undergo a screening period before starting treatment, which can continue for up to 24 months or until disease progression or unacceptable side effects occur. Follow-up periods monitor safety, efficacy, and long-term survival, with total involvement expected to last about 36 months unless ongoing benefit warrants extended treatment. Researchers evaluate dose-limiting toxicities, adverse events, tumor response rates, progression-free survival, and pharmacokinetics to understand treatment effects and participant outcomes.

Age: 18Years +All GendersPhase 1Phase 2
86 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are conducting a large community-based observational study in Yangzhou to assess the effectiveness of a polygene methylation test in screening for colorectal cancer. This study aims to evaluate how well this test detects colorectal cancer and precancerous lesions in real-world settings by enrolling 80,000 permanent residents aged 40 to 74 years. The study will last five years and is jointly developed by Northern Jiangsu Peoples Hospital and Shanghai Kunyuan Biological Technology Co., LTD. At the start, participants will complete a colorectal cancer risk questionnaire and provide samples for the polygene methylation test. Those with positive test results will undergo further testing including a fecal immunochemistry test, blood carcinoembryonic antigen test, and colonoscopy within three months. These follow-up tests help confirm the presence of colorectal cancer or precancerous lesions. Participants will be followed by phone at 1, 2, 3, 4, and 5 years after the initial screening to collect medical history and survival outcomes. The study will use colonoscopy and pathology results to confirm diagnoses. Researchers will assess outcomes such as the sensitivity, specificity, and detection rates of the screening methods, with study endpoints reached when colorectal cancer or related lesions are diagnosed or treated.

Age: 40Years - 74YearsAll Genders
2 locations
G

Actively Recruiting

Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.

Age: 18Years +All GendersPhase 3
333 locations
A

Actively Recruiting

Researchers are investigating a multi-modal artificial intelligence AI framework designed to improve the classification and genetic subtyping of lung cancer using PETCT imaging and clinical information such as age, gender, smoking history, family cancer history, and tumor biomarkers. This observational study aims to accurately distinguish between small cell lung cancer and non-small cell lung cancer NSCLC, and then further divide NSCLC into subtypes including adenocarcinoma and squamous cell carcinoma. Additionally, the study evaluates the prediction of the EGFR gene mutation status, especially common in lung adenocarcinoma patients. All participants undergo a pre-treatment 18F-FDG PETCT scan. The study cohort is divided into training, validation, test, and prospective groups for analysis. The AI framework is developed and tested using retrospective data, followed by prospective validation to assess the models accuracy in pathological and genetic subtyping. This structured approach aims to facilitate a precise and hierarchical stratification process for lung cancer patients. Participants will provide clinical information and have their PETCT images analyzed as part of the study. Researchers will measure the accuracy of lung cancer subtype differentiation and EGFR mutation prediction over a one-year period. The study involves no drug interventions, focusing on imaging data, clinical records, and AI model development. The total participation time varies, with assessments primarily based on imaging and clinical data collected before treatment begins.

Age: 18Years +All Genders
9 locations
E

Actively Recruiting

Researchers are evaluating ASP5541, a new form of abiraterone acetate given by muscle injection, in men with advanced prostate cancer. The study compares ASP5541, with or without prednisoneprednisolone, to standard abiraterone acetate tablets plus prednisoneprednisolone. It aims to assess the safety and effectiveness of ASP5541 in men with metastatic hormone-sensitive and metastatic castration-resistant prostate cancer who have not previously received androgen receptor pathway inhibitors. Participants are assigned to one of three groups men with metastatic castration-resistant prostate cancer receive either ASP5541 plus prednisoneprednisolone or abiraterone acetate plus prednisoneprednisolone men with metastatic hormone-sensitive prostate cancer receive either ASP5541 alone or abiraterone acetate with prednisoneprednisolone and Japanese men with either cancer type receive ASP5541 with prednisoneprednisolone. ASP5541 is administered by injection every 12 weeks, prednisoneprednisolone is taken orally once or twice daily depending on cancer type, and abiraterone acetate is taken daily as tablets. All participants continue standard androgen deprivation therapy. During the study, participants will have regular clinic visits for health monitoring and safety checks, with some checking blood pressure weekly at home. Imaging scans and laboratory tests will assess cancer progression and treatment effects. Researchers will measure outcomes such as prostate-specific antigen levels, safety events, testosterone suppression, and cancer progression. The study includes long-term follow-up for up to 84 months and aims to provide detailed information on the safety and efficacy of ASP5541 compared to existing treatments.

Age: 18Years +MALEPhase 2
54 locations
E

Actively Recruiting

Researchers are evaluating the drug WS016 to treat hyperkalemia, a condition characterized by high potassium levels in the blood. This open-label Phase 3 clinical trial includes two phases a corrective phase aiming to reduce potassium levels within 24 to 72 hours, followed by a maintenance phase to keep potassium levels normal over a 12-month period in participants who meet specific criteria after the first phase. Participants first receive oral doses of WS016 12 grams three times daily during the corrective phase. Those whose potassium levels normalize enter the maintenance phase, receiving WS016 once daily at 12 grams, with dose adjustments based on potassium levels over the following 12 months. This study evaluates the long-term safety and effectiveness of WS016 in maintaining normal potassium levels. Throughout the study, participants undergo regular blood tests to monitor potassium levels and safety assessments during both phases. Researchers measure the percentage of participants maintaining potassium at or below 5.0 mmolL during the maintenance phase. Adverse events and changes in potassium are tracked closely. The total participation may last over a year, including both treatment phases and follow-up assessments.

Age: 18Years +All GendersPhase 3
50 locations

1-10 of 128

1